|Day Low/High||1.86 / 1.94|
|52 Wk Low/High||1.10 / 2.63|
Event held in conjunction with Super Bowl LII will focus on key issues in neurological medicine and women's brain health
Off-the-shelf stem cell therapy has potential to extend treatment window and enhance recovery for stroke patients
Technology transfer of stem cell production methods in preparation for potential commercialization in Japan following TREASURE clinical study
Investors in Athersys Inc saw new options begin trading this week, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 228 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 866,866 share increase in total short interest for Athersys Inc , to 4,997,005, an increase of 20.99% since 04/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Lancet Neurology/Stem Cells publications provide further clarity of MultiStem mechanisms of benefit - modulating inflammatory response and immune system - enhancing recovery
Details of Healios' Phase II/III trial (HLCM051) being presented by stroke expert and lead investigator Dr. Kyohiro Houkin
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.